Pacific Blue™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_Blue_091207
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) Pacfic Blue™ (filled histogram) or rat IgG2b, κ Pacific Blue™ isotype control (open histogram).
  • GK1dot5_Blue_091207
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) Pacfic Blue™ (filled histogram) or rat IgG2b, κ Pacific Blue™ isotype control (open histogram).
Compare all formats See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
100427 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100428 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  3. Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed
  4. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  5. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  6. Giampaolo S, et al. 2023. iScience. 26:106234. PubMed
  7. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  8. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  9. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  10. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  11. McAlpine CS, et al. 2022. J Exp Med. 219: . PubMed
  12. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  13. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  14. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  15. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  16. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  17. Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed
  18. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  19. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  20. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  21. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  22. Thwe PM et al. 2017. Cell metabolism. 26(3):558-567 . PubMed
  23. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  24. Manion KP, et al. 2020. PLoS One. 15:e0236664. PubMed
  25. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  26. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  27. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  28. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  29. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  30. MaruYama T 2015. Biochem Biophys Res Commun. 464: 586-589. PubMed
  31. Price J, et al. 2015. Diabetes. 64: 3521 - 3531. PubMed
  32. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  33. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  34. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  35. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  36. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  37. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  38. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  39. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  40. Sawant D, et al. 2014. J Immunol. 192:2904. PubMed
  41. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  42. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  43. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  44. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  45. Picard M, et al. 2020. Cell Death Differ. . PubMed
  46. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  47. Green WD, et al. 2022. J Leukoc Biol. 111:147. PubMed
  48. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  49. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  50. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  51. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  52. Ma Y, et al. 2020. Cell Prolif. 53:e12802. PubMed
  53. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  54. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  55. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  56. Teo T, et al. 2013. J Immunol. 190:259. PubMed
  57. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  58. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  59. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  60. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  61. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  62. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
  63. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  64. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  65. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  66. Parodi B, et al. 2021. Front Immunol. 12:655212. PubMed
  67. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  68. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  69. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  70. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  71. Zhang L, et al. 2020. Cell. 442:181. PubMed
  72. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  73. Morawski P, et al. 2013. J Biol Chem. 288:24494. PubMed
  74. Goubet AG, et al. 2021. Cell Death Differ. 28:2276. PubMed
  75. Habener A, et al. 2021. J Allergy Clin Immunol. 147:2281. PubMed
  76. Eitas T, et al. 2014. J Biol Chem. 289:4173. PubMed
  77. Ang QY, et al. 2020. Cell. 181(6):1263-1275.e16. PubMed
  78. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  79. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  80. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  81. Hsieh WC, et al. 2018. Nat Commun. 9:463. PubMed
  82. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  83. Moyat M, et al. 2022. Mucosal Immunol. 15:1283. PubMed
  84. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  85. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  86. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_493646 (BioLegend Cat. No. 100427)
AB_493647 (BioLegend Cat. No. 100428)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV™ 395 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account